A fixed-dose combination of pangenotypic direct-acting antivirals was “‘highly effective” in treatment-native patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3, a study presented at The Liver Meeting (R) 2016 has shown.
Newsroom
A fixed-dose combination of pangenotypic direct-acting antivirals was “‘highly effective” in treatment-native patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3, a study presented at The Liver Meeting (R) 2016 has shown.